Crescent Biopharma, Inc.

NASDAQ:CBIO

Biotechnology

Healthcare
$12.40 -2.69%

-$0.49 today

Market cap
$482.30M
Beta
1.15
P/E (TTM)
-3.3
EPS (TTM)
-$5.33
52W Low $8.72High $27.41

Volume 0.33M

Average 0.28M

CBIO Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Crescent Biopharma, Inc.NASDAQ: CBIO

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin at 100.0%

Gross margin was 100.0% in Q1 FY2026. On a trailing-twelve-month basis it was 100.0%. Over 3 fiscal years it widened by 0.0 pp.

Context

  • Gross margin widened in 0 of the last 2 fiscal years.
  • FY2025 was the highest level in the 3 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
100.0%+0.0 pp QoQ
Last fiscal yearDec 2025
100.0%— YoY
LTMMar 2026
100.0%— YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years+0.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
100.0%
Year-over-year change
—

Gross Margin vs competitors

How CBIO compares with its peers on the latest reported figures

  • CBIO's LTM Mar 2026 gross margin of 100.0% is the highest of the 7 companies compared; the peer median is 79.0%.
  • Over three fiscal years its change of +0.0 pp compares with a peer median of +0.0 pp.
CBIO Competitors Peer median
Gross Margin for CBIO and competitors
Company Period LTM level YoY 3-year change
CBIOCrescent Biopharma, Inc.LTM Mar 2026100.0% —+0.0 pp
CTMXCytomX Therapeutics, Inc.LTM Mar 202699.3% -0.7 pp+0.0 pp
RCUSArcus Biosciences, Inc.LTM Jun 202694.0% -6.0 pp-4.0 pp
CGENCompugen Ltd.LTM Mar 202688.1% +17.9 pp+0.3 pp
MGNXMacroGenics, Inc.LTM Mar 202669.9% +7.9 pp-24.0 pp
ZYMEZymeworks Inc.LTM Sep 202668.6% -31.4 pp+0.0 pp
CLDXCelldex Therapeutics, Inc.LTM Sep 2026-662.5% +5797.5 pp+3489.9 pp
VRXAVeraxa Biotech Holding AG—— ——
CMPXCompass Therapeutics, Inc.FY2025— ——
NBPNovaBridge BiosciencesFY2025— ——
CNTXContext Therapeutics Inc.FY2025— ——
Peer median (excluding CBIO) 79.0%+3.6 pp+0.0 pp

Competitors are the stored peer set for CBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.16M75K10K010.84M
Cost of Revenue00000
Gross Profit1.16M75K10K010.84M
Gross Margin100.0%100.0%100.0%—100.0%
Research & Development47.49M28.39M20.07M28.06M138.09M
Selling, General & Admin17.12M19.09M19.21M16.32M25.39M
Operating Expenses64.61M47.48M39.29M49.9M163.48M
Depreciation & Amortization264.6K207.15K153.3K35.17K84K
EBITDA(63.18M)(47.2M)(39.12M)(44.17M)(149.67M)
EBITDA Margin-5447.9%-62927.6%-391213.5%—-1380.2%
Operating Income(63.45M)(47.4M)(39.28M)(49.9M)(152.63M)
Operating Margin-5470.7%-63204.4%-392752.9%—-1407.5%
Interest Income19.77K714.52K2.38M1M2.88M
Interest Expense000852K2.19M
Other Income / Expenses19.77K714.96K2.38M1.37M690K
Income Before Tax(63.43M)(46.69M)(36.9M)(48.52M)(151.94M)
Pre-Tax Margin-5469.0%-62251.1%-368987.8%—-1401.2%
Income Tax Expense00002M
Net Income(63.43M)(46.69M)(36.9M)(48.52M)(153.94M)
Net Margin-5469.0%-62251.7%-368994.2%—-1419.6%
EPS (Basic)(1.23)(0.89)(0.58)(1.40)(14.78)
EPS (Diluted)(1.23)(0.89)(0.58)(1.40)(14.78)
Weighted Avg Shares51.45M52.53M63.34M19.5M10.41M
Weighted Avg Shares (Diluted)51.45M52.53M63.34M19.5M10.41M

Crescent Biopharma, Inc.

NASDAQ:CBIO

Intrinsic Alpha fair value

Locked

Current Price

$12.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.